Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance

View ORCID ProfileStéphane Le Vu, Gabrielle Jones, François Anna, Thierry Rose, Jean-Baptiste Richard, Sibylle Bernard-Stoecklin, Sophie Goyard, Caroline Demeret, Olivier Helynck, Corinne Robin, Virgile Monnet, Louise Perrin de Facci, Marie-Noelle Ungeheuer, Lucie Léon, Yvonnick Guillois, Laurent Filleul, Pierre Charneau, Daniel Lévy-Bruhl, Sylvie van der Werf, View ORCID ProfileHarold Noel
doi: https://doi.org/10.1101/2020.10.20.20213116
Stéphane Le Vu
1Division of Infectious Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stéphane Le Vu
  • For correspondence: stephane.le-vu@santepubliquefrance.fr
Gabrielle Jones
1Division of Infectious Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Anna
14Theravectys, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thierry Rose
7Unit of Lymphocyte Cell Biology, Immunology Department, INSERM 1221
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Baptiste Richard
2Division of Data Sciences
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sibylle Bernard-Stoecklin
1Division of Infectious Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophie Goyard
7Unit of Lymphocyte Cell Biology, Immunology Department, INSERM 1221
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Demeret
8Unit of Molecular Genetics of RNA Viruses, UMR 3569 CNRS, University of Paris-Diderot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Helynck
9Unit of Chemistry and Biocatalysis, UMR 3523 CNRS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Corinne Robin
12Institut Pasteur, Paris, France; Cerba Healthcare Division, Cerba Xpert, St Ouen L’Aumone, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Virgile Monnet
13Eurofins Biomnis Sample Library, Eurofins-Biomnis, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louise Perrin de Facci
10ICAReB Biobanking Platform, Center for Translational Science
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Noelle Ungeheuer
10ICAReB Biobanking Platform, Center for Translational Science
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucie Léon
3Regional Division, Regional office – French Caribbean
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yvonnick Guillois
4Regional office – Brittany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Filleul
5Regional office – Nouvelle Aquitaine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Charneau
6Unit of Molecular Virology and Vaccinology, Virology Department Santé publique France, Saint-Maurice, France
14Theravectys, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Lévy-Bruhl
1Division of Infectious Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvie van der Werf
8Unit of Molecular Genetics of RNA Viruses, UMR 3569 CNRS, University of Paris-Diderot
11National Reference Center for Respiratory infections viruses
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harold Noel
1Division of Infectious Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Harold Noel
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Assessment of cumulative incidence of SARS-CoV-2 infections is critical for monitoring the course and the extent of the epidemic. As asymptomatic or mild cases were typically not captured by surveillance data in France, we implemented nationwide serological surveillance. We present estimates for prevalence of anti-SARS-CoV-2 antibodies in the French population and the proportion of infected individuals who developed potentially protective neutralizing antibodies throughout the first epidemic wave.

Methods We performed serial cross-sectional sampling of residual sera over three periods: prior to (9-15 March), during (6-12 April) and following (11-17 May) a nationwide lockdown. Each sample was tested for anti-SARS-CoV-2 IgG antibodies targeting the Nucleoprotein and Spike using two Luciferase-Linked ImmunoSorbent Assays, and for neutralising antibodies using a pseudo-neutralisation assay. We fitted a general linear mixed model of seropositivity in a Bayesian framework to derive prevalence estimates stratified by age, sex and region.

Findings In total, sera from 11 021 individuals were analysed. Nationwide seroprevalence of SARS-CoV-2 antibodies was estimated at 0.41% [0.05−0.88] mid-March, 4.14% [3.31−4.99] mid-April and 4.93% [4.02−5.89] mid-May. Approximately 70% of seropositive individuals had detectable neutralising antibodies. Seroprevalence was higher in regions where circulation occurred earlier and was more intense. Seroprevalence was lowest in children under 10 years of age (2.72% [1.10−4.87]).

Interpretation Seroprevalence estimates confirm that the nationwide lockdown substantially curbed transmission and that the vast majority of the French population remains susceptible to SARS-CoV-2. Low seroprevalence in school age children suggests limited susceptibility and/or transmissibility in this age group. Our results show a clear picture of the progression of the first epidemic wave and provide a framework to inform the ongoing public health response as viral transmission is picking up again in France and globally.

Funding Santé publique France.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Santé publique France provided funding to the NRC and to the two centralising biobanks to cover sample collection, preparation, transport, and analysis costs. The funder had no role in analysis, interpretation of data or writing of the report. SLV, GJ and HN had full access to all the data and had responsibility to submit for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Authorization for conservation and preparation of elements of the human body for scientific use was granted to the two biobanks by the bioethics committee from General Board for Research and Innovation (DGRI) of French Ministry of Higher Education and Research (approvals AC-2015-2418 and AC-2018-3329). Information regarding secondary use of de-identified residual sera for approved research studies was systematically displayed and orally communicated at the primary clinical laboratories. The Ethics Committee (Comité de Protection des Personnes Ile-de-France VI, CHU Pitié-Salpétri&egravere Hospital, Paris, France) waived the need for ethical approval for the collection, analysis and publication of the retrospectively obtained and anonymized specimens and data for this study. This work was carried out following regulations of the French Public Health Code (articles L. 1413-7 and L. 1413-8) and the French Commission for Data Protection (CNIL).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data from the analysis can be made available upon request to the corresponding author and might require partial aggregation or downsampling to protect patient privacy.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 21, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance
Stéphane Le Vu, Gabrielle Jones, François Anna, Thierry Rose, Jean-Baptiste Richard, Sibylle Bernard-Stoecklin, Sophie Goyard, Caroline Demeret, Olivier Helynck, Corinne Robin, Virgile Monnet, Louise Perrin de Facci, Marie-Noelle Ungeheuer, Lucie Léon, Yvonnick Guillois, Laurent Filleul, Pierre Charneau, Daniel Lévy-Bruhl, Sylvie van der Werf, Harold Noel
medRxiv 2020.10.20.20213116; doi: https://doi.org/10.1101/2020.10.20.20213116
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance
Stéphane Le Vu, Gabrielle Jones, François Anna, Thierry Rose, Jean-Baptiste Richard, Sibylle Bernard-Stoecklin, Sophie Goyard, Caroline Demeret, Olivier Helynck, Corinne Robin, Virgile Monnet, Louise Perrin de Facci, Marie-Noelle Ungeheuer, Lucie Léon, Yvonnick Guillois, Laurent Filleul, Pierre Charneau, Daniel Lévy-Bruhl, Sylvie van der Werf, Harold Noel
medRxiv 2020.10.20.20213116; doi: https://doi.org/10.1101/2020.10.20.20213116

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (166)
  • Anesthesia (49)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (188)
  • Epidemiology (5206)
  • Forensic Medicine (3)
  • Gastroenterology (194)
  • Genetic and Genomic Medicine (747)
  • Geriatric Medicine (76)
  • Health Economics (212)
  • Health Informatics (691)
  • Health Policy (350)
  • Health Systems and Quality Improvement (221)
  • Hematology (98)
  • HIV/AIDS (161)
  • Infectious Diseases (except HIV/AIDS) (5798)
  • Intensive Care and Critical Care Medicine (355)
  • Medical Education (101)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (754)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (230)
  • Oncology (473)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (93)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (138)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (851)
  • Public and Global Health (1987)
  • Radiology and Imaging (342)
  • Rehabilitation Medicine and Physical Therapy (155)
  • Respiratory Medicine (282)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (74)
  • Surgery (107)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)